Nothing Special   »   [go: up one dir, main page]

HK1200057A1 - 使用胎盤鑑定抗癌化合物 - Google Patents

使用胎盤鑑定抗癌化合物

Info

Publication number
HK1200057A1
HK1200057A1 HK15100631.8A HK15100631A HK1200057A1 HK 1200057 A1 HK1200057 A1 HK 1200057A1 HK 15100631 A HK15100631 A HK 15100631A HK 1200057 A1 HK1200057 A1 HK 1200057A1
Authority
HK
Hong Kong
Prior art keywords
placenta
identification
antitumor compounds
antitumor
compounds
Prior art date
Application number
HK15100631.8A
Other languages
English (en)
Inventor
Robert J Hariri
Mohit B Bhatia
Qian Ye
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of HK1200057A1 publication Critical patent/HK1200057A1/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15100631.8A 2012-02-23 2015-01-20 使用胎盤鑑定抗癌化合物 HK1200057A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602524P 2012-02-23 2012-02-23
PCT/US2013/027288 WO2013126674A1 (en) 2012-02-23 2013-02-22 Identification of antitumor compounds using placenta

Publications (1)

Publication Number Publication Date
HK1200057A1 true HK1200057A1 (zh) 2015-07-31

Family

ID=49006227

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15100631.8A HK1200057A1 (zh) 2012-02-23 2015-01-20 使用胎盤鑑定抗癌化合物
HK18116495.6A HK1257535A1 (zh) 2012-02-23 2018-12-24 使用胎盤鑑定抗腫瘤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18116495.6A HK1257535A1 (zh) 2012-02-23 2018-12-24 使用胎盤鑑定抗腫瘤化合物

Country Status (5)

Country Link
US (1) US9575054B2 (zh)
EP (2) EP2816894B1 (zh)
ES (1) ES2666576T3 (zh)
HK (2) HK1200057A1 (zh)
WO (1) WO2013126674A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3010904C (en) * 2016-01-08 2024-03-05 Cryolife, Inc. Human placental tissue graft products, methods, and apparatuses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5192312A (en) 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
CA2447690A1 (en) * 2001-05-25 2002-12-05 Clontech Laboratories, Inc. Kindling fluorescent proteins and methods for their use
US20030187515A1 (en) * 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
CA2495935A1 (en) * 2002-08-13 2004-02-19 The Board Of Trustees Of The University Of Illinois Screening strategy for anticancer drugs
CA2530416C (en) * 2003-06-27 2015-08-25 Ethicon, Incorporated Postpartum cells derived from placental tissue, and methods of making and using the same
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
PT1957633E (pt) 2005-10-13 2014-03-25 Anthrogenesis Corp Imunomodulação utilizando células estaminais da placenta
ES2671355T3 (es) 2005-12-29 2018-06-06 Anthrogenesis Corporation Poblaciones de células madre placentarias
EP2115456A2 (en) * 2007-02-01 2009-11-11 Dana-Farber Cancer Institute, Inc. Cell co-culture systems and uses thereof
CN103356711A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
RS53841B1 (en) 2007-09-28 2015-06-30 Anthrogenesis Corporation TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSES AND INTERMEDIATE CELLS KILLED ORIGINATING IN HUMAN PLACENTA
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
WO2010021756A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2275442A1 (en) * 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
US9034386B2 (en) * 2009-12-17 2015-05-19 Queen's University At Kingston Decellularized adipose tissue

Also Published As

Publication number Publication date
US20150017663A1 (en) 2015-01-15
EP2816894B1 (en) 2018-01-03
EP2816894A4 (en) 2015-06-24
EP3338548A1 (en) 2018-06-27
HK1257535A1 (zh) 2019-10-25
WO2013126674A1 (en) 2013-08-29
WO2013126674A9 (en) 2017-06-08
EP2816894A1 (en) 2014-12-31
ES2666576T3 (es) 2018-05-07
US9575054B2 (en) 2017-02-21
EP3338548B1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
HK1203498A1 (zh) 四氫吡唑並嘧啶化合物
HK1198761A1 (zh) 咪唑並吡咯啶酮化合物
EP2925129A4 (en) PRO-NEUROGENIC COMPOUNDS
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2861588A4 (en) NEW THERAPEUTIC AGENTS FOR BRAIN CANCER
HK1206726A1 (zh) 咪唑並三嗪酮化合物
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
HK1211283A1 (zh) 化合物
HK1211927A1 (zh) 聚蛋白多糖酶抑制劑
HK1209391A1 (zh) 車輛定位
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
GB201209096D0 (en) Compounds
HK1209287A1 (zh) 配方增强劑
GB201202393D0 (en) Polymorphs
HK1206356A1 (zh) -取代的氰基吡唑化合物
GB201219820D0 (en) Compounds
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201220418D0 (en) Identification of materials
GB201217310D0 (en) Compounds
EP2835001A4 (en) IDENTIFICATION FOR DEVICES
HK1257535A1 (zh) 使用胎盤鑑定抗腫瘤化合物
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-